【李氏大药厂:专有ADC项目ZK2401新药临床试验申请获NMPA受理】李氏大药厂公告,公司就专有ADC项目ZK2401于中国提交的新药临床试验申请,已于2026年7月29日获得中国国家药品监督管理局药品评审中心受理。ZK2401为基于公司自主研发抗PD-L1抗体索卡佐利单抗并偶联新型拓扑异构酶I抑制剂载荷的ADC项目,是公司ADC平台首个项目。预期审评期约30个工作日,最早有望于2026年9月获得临床试验批准。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.